A Multinational, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, 3-Way Crossover Study in Migraine Patients, Treated With Two Doses of BGC20-1531 and Placebo.

Trial Profile

A Multinational, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, 3-Way Crossover Study in Migraine Patients, Treated With Two Doses of BGC20-1531 and Placebo.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2016

At a glance

  • Drugs AP 1531 (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Therapeutic Use
  • Sponsors BTG; BTG International
  • Most Recent Events

    • 12 Jan 2016 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
    • 12 Jul 2010 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top